PCM
ALT icon

Portolan Capital Management’s Altimmune ALT Stock Holding History

Portolan Capital Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-60,976
Closed -$374K – 134
2024
Q3 		$374K Sell
60,976
-579,266
-90% -$3.92M 0.03% 129
2024
Q2 		$4.26M Sell
640,242
-247,013
-28% -$1.82M 0.35% 93
2024
Q1 		$9.03M Buy
+887,255
New +$9.02M 0.69% 52

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Portolan Capital Management's ALT Position: Q4 2024 in Review

Portolan Capital Management sold out of Altimmune (ALT) in Q4 2024, closing a stake of 60,976 shares — an estimated $374K sold.

Portolan Capital Management first reported a position in ALT in Q1 2024 and held it in 3 quarters. The position peaked at $9.03M in Q1 2024. 182 funds tracked by Wall St. Rank hold ALT as of Q4 2024.

  • Portolan Capital Management reported no remaining Altimmune position as of Q4 2024 after selling out during the quarter.
  • Portolan Capital Management sold 60,976 Altimmune shares in Q4 2024, an estimated $374K.
  • Portolan Capital Management first reported a position in Altimmune in Q1 2024 and held it in 3 quarters.
  • Portolan Capital Management's Altimmune position peaked at $9.03M in Q1 2024.
  • 182 funds tracked by Wall St. Rank held Altimmune as of Q4 2024.

Based on Portolan Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.